Antibody COVID-19 Therapies Back in China Spotlight Amid Infection Surge
Chinese developers forge ahead with research into antibody therapies for COVID-19 as coronavirus variants gain a toe-hold in the country.
You may also be interested in...
Chinese venture Brii seeks US emergency authorization for its antibody combo, as Chugai aims for wider use of its antibody cocktail in Japan and two other Chinese firms link up on an oral antiviral.
Also, Moderna completed the submission of the BLA for mRNA-1273’s FDA approval, Pfizer starts a rolling submission for a booster shot and Brii Biosciences announced data for its two-antibody antiviral cocktail, and Japan withdraws selected lots of Moderna's vaccine over contamination worries.
Amid surging infections in several cities including Wuhan, China is urging vaccination among unvaccinated people, but a booster shot may be needed soon to address a low efficacy among Chinese vaccines, some say.